PMID- 24092562
OWN - NLM
STAT- MEDLINE
DCOM- 20140623
LR  - 20211021
IS  - 1179-1918 (Electronic)
IS  - 1173-2563 (Print)
IS  - 1173-2563 (Linking)
VI  - 33
IP  - 12
DP  - 2013 Dec
TI  - Isolated and spontaneous correction of proximal interphalangeal joint 
      contractures in Dupuytren's disease: an exploratory analysis of the efficacy and 
      safety of collagenase Clostridium histolyticum.
PG  - 905-12
LID - 10.1007/s40261-013-0139-0 [doi]
AB  - BACKGROUND AND OBJECTIVE: Dupuytren's contractures affecting proximal 
      interphalangeal (PIP) joints are challenging to treat. We explored the effects of 
      collagenase Clostridium histolyticum (CCH) on PIP joint contractures after 
      injection of an affected metacarpophalangeal (MP) joint in the same finger and 
      after injection of an isolated PIP joint contracture. METHODS: Two patient 
      subsets were evaluated: those with MP/PIP joints contractures in the same finger, 
      but only the MP joint contractures were treated (Group A); and those with 
      isolated PIP joint contractures that were treated (Group B). Endpoints included 
      correction and improvement in contracture. Fixed-flexion contracture (FFC) and 
      range of motion (ROM) were also assessed; adverse events (AEs) were monitored. 
      RESULTS: In Group A, 28 and 43 % of PIP contractures spontaneously corrected 
      after the first and last injection of CCH, respectively, for MP contractures; 40 
      and 63 %, respectively, improved. In Group B, 31 and 39 % of PIP joint 
      contractures corrected after the first and last injection of CCH, respectively, 
      56 and 66 %, respectively, improved. In Groups A and B, FFC improvements were 
      largest after the last injection; ROM improvements were largest after the last 
      injection in Group A and third injection in Group B. For 46 and 44 % of patients 
      in Groups A and B, respectively, the first injection was the last injection. In 
      Group B, the median (minimum, maximum) injections/joint was 1.0 (1.0, 4.0). 
      Nearly all patients (98 %) experienced >/=1 AE; most were injection-site reactions. 
      CONCLUSIONS: The efficacy of CCH for improving PIP joint contracture was similar 
      whether treated in isolation or after treatment of an MP joint contracture.
FAU - Hayton, Michael J
AU  - Hayton MJ
AD  - Wrightington Hospital, Hall Lane, Appley Bridge, Lancashire, WN6 9EP, UK, 
      mikehayton@gmail.com.
FAU - Bayat, Ardeshir
AU  - Bayat A
FAU - Chapman, Douglass S
AU  - Chapman DS
FAU - Gerber, Robert A
AU  - Gerber RA
FAU - Szczypa, Piotr P
AU  - Szczypa PP
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - New Zealand
TA  - Clin Drug Investig
JT  - Clinical drug investigation
JID - 9504817
RN  - EC 3.4.24.- (Collagenases)
SB  - IM
MH  - Aged
MH  - Clostridium histolyticum/*enzymology
MH  - Collagenases/adverse effects/*therapeutic use
MH  - Dupuytren Contracture/*drug therapy/physiopathology
MH  - Female
MH  - Fingers/*physiopathology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Range of Motion, Articular
PMC - PMC3830197
EDAT- 2013/10/05 06:00
MHDA- 2014/06/24 06:00
PMCR- 2013/10/05
CRDT- 2013/10/05 06:00
PHST- 2013/10/05 06:00 [entrez]
PHST- 2013/10/05 06:00 [pubmed]
PHST- 2014/06/24 06:00 [medline]
PHST- 2013/10/05 00:00 [pmc-release]
AID - 139 [pii]
AID - 10.1007/s40261-013-0139-0 [doi]
PST - ppublish
SO  - Clin Drug Investig. 2013 Dec;33(12):905-12. doi: 10.1007/s40261-013-0139-0.